FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer

FDA has changed the approved uses of the immunotherapy drugs pembrolizumab (Keytruda) and atezolizumab (Tecentriq) to treat the most common form of bladder cancer. The change is based on whether patients’ tumors have a specific biomarker.

Cancer Currents: An NCI Cancer Research Blog